Clinical trials: Affective Disorder
Bipolar Disorder
A Study of LY2979165 in Healthy Subjects
This is a two part study. Part A is a multiple-ascending dose study in up to 6 different groups of healthy subjects, with approximately 12 subjects in each of the groups.
- Trial name
- NCT01383967
- Testing
- LY2979165
- Where
- Singapore
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms
The purpose of this study is to evaluate the efficacy and safety of long term escitalopram treatment in participants with Major Depressive Disorder (MDD) with associated anxiety symptoms.
- Trial name
- Lexapro (NCT01814098)
- Testing
- Escitalopram
- Where
- 10 sites in China
- Volunteers
- 318 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Vitiligo, Depressive Episode
Mental Health Associations With Vitiligo
This cohort study is a large population-based study in the UK to determine the risks of comorbid mental health conditions (including depression, anxiety and other potential psychological complications of vitiligo) in adults with…
- Conditions
- Vitiligo, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04953338
- Testing
- Exposure of mental health condtion of interest
- Where
- United Kingdom
- Volunteers
- 36,104 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Major Depressive Disorder
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Emerge
- Trial name
- NCT06941844
- Testing
- DT120
- Where
- 22 sites in United States
- Volunteers
- 149 people
- Sponsor
- Definium Therapeutics US, Inc.
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
The purpose of this study is to assess the efficacy and safety of multiple doses of vortioxetine, once daily (QD), in participants with major depressive disorder.
- Trial name
- NCT01255787
- Testing
- Vortioxetine
- Where
- 70 sites in Croatia, Finland and 14 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Major Depressive Disorder
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode.
- Trial name
- NCT01684163
- Testing
- GLYX-13 5 mg/kg, GLYX-13 10 mg/kg
- Where
- 26 sites in United States
- Volunteers
- 369 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Bipolar Disorder
Topiramate Versus Placebo as add-on Treatment in Patients With Bipolar Disorder in the Outpatient Setting
The purpose of this study is to assess the efficacy and safety of adding topiramate as compared to placebo to the medications a patient with bipolar disorder is already taking (lithium or valproate) to see if adding topiramate…
- Trial name
- NCT00237289
- Testing
- topiramate
- Volunteers
- 287 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Depressive Disorder, Major
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities).
- Trial name
- NCT06982820
- Testing
- Prism Training
- Where
- 3 sites in United States, Israel
- Volunteers
- 170 people
- Sponsor
- GrayMatters Health Ltd.
Schizophrenia, Major Depressive Disorder
"Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"
The objective of this post marketing surveillance is to further gather local data on the safety and efficacy of Brexpiprazole (RexultiTM) Film-coated Tablet in the treatment of schizophrenia and adjunctive therapy of Major…
- Trial name
- RAISE (NCT04641780)
- Testing
- Brexpiprazole
- Where
- Philippines
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical, Inc., Philippines
Depressive Disorder, Major
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
This is a Phase 1, conventional, double-blind, placebo-controlled, single-center clinical study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of SUVN-911 or placebo will be orally…
- Trial name
- SUVN-911 (NCT03155503)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01372150
- Testing
- desvenlafaxine succinate sustained release, fluoxetine
- Where
- 43 sites in United States, Mexico
- Volunteers
- 340 people
- Sponsor
- Pfizer
Bipolar Disorder
Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients
The study will be a multi-center, parallel, group, placebo control, double-blind, randomized controlled trial of lamictal as add-on maintenance treatment in pediatric outpatients (aged 10 to 17 years) diagnosed with Bipolar I…
- Trial name
- NCT00723450
- Testing
- lamictal
- Where
- 46 sites in United States
- Volunteers
- 301 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Major Depressive Disorder
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT06058039
- Testing
- NMRA-335140
- Where
- 71 sites in United States, Bulgaria and 6 more
- Volunteers
- 422 people
- Sponsor
- Neumora Therapeutics, Inc.
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01377194
- Testing
- Levomilnacipran ER
- Where
- 51 sites in United States, Canada
- Volunteers
- 568 people
- Sponsor
- Forest Laboratories
Depressive Disorder, Major
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers
Bupropion is used in psychological disorder mainly in major depressive disorder (MDD). In China, buproprion Immediate Release (IR) and Sustained Release (SR) tablet have been in market for the treatment of MDD.
- Trial name
- NCT02698553
- Testing
- Bupropion HCl XL tablet 150mg, Bupropion HCl XL tablet 300mg
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder (MDD)
Effects Of Antidepressants On Sexual Functioning In Adults
This study will evaluate the effects of two antidepression medications on sexual functioning.
- Trial name
- NCT00051272
- Testing
- Extended-release Bupropion Hydrochloride
- Where
- 24 sites in United States
- Volunteers
- 425 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.
- Trial name
- Reliance III (NCT05081167)
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 232 people
- Sponsor
- Relmada Therapeutics, Inc.
Depression, Major Depressive Disorder
Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements
The purpose of the current study is to perform a unified, homogeneous data collection protocol that includes a large cohort of patients undergoing different treatment options for Major Depressive Disorder (MDD) as an avenue for…
- Trial name
- PREDICT (NCT06002100)
- Testing
- fNIRS measurement
- Where
- 10 sites in United States
- Volunteers
- 540 people
- Sponsor
- Kernel
Bipolar Depression, Suicidal Ideation and Behavior
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
NMDA antagonist drugs have shown to reduce symptoms of depression and suicidal ideation. NeuroRx has developed NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for oral use in the treatment of bipolar depression…
- Trial name
- NCT03395392
- Testing
- NRX-101, Lurasidone HCl
- Where
- 14 sites in United States
- Volunteers
- 74 people
- Sponsor
- NeuroRx, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.